A confirmatory factor analysis was performed to examine the factorial structure of a battery of working memory measures across two Arab cultures (Kuwait and Egypt). The battery of tests was administered to a sample of 384 children: 192 primary-school Kuwaiti children (96 boys, 96 girls; M age = 10.0 yr., SD = 1.0) and 192 primary-school Egyptian children (96 boys, 96 girls; M age = 10.0 yr., SD = 1.2). The multi-group confirmatory factor analysis revealed configural, metric, scalar, and strict invariances across the two cultures. This implies that working memory can be conceptualized similarly by Kuwaiti and Egyptian children and was measured in the same way in both cultures. Both within-groups individual differences and between-groups differences in means reflected differences in the underlying latent construct.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2466/22.03.08.PMS.115.4.43-59 | DOI Listing |
Alzheimers Dement
December 2024
Centre for Addiction and Mental Health, Toronto, ON, Canada.
Background: Dysregulated GABA/somatostatin (SST) signaling has been implicated in psychiatric and neurodegenerative disorders. The inhibition of excitatory neurons by SST+ interneurons, particularly through α5-containing GABAA receptors (α5-GABAAR), plays a crucial role in mitigating cognitive functions. Previous research demonstrated that an α5-positive allosteric modulator (α5-PAM) mitigates working memory deficits and reverses neuronal atrophy in aged mice.
View Article and Find Full Text PDFBackground: Selecting the optimal dose for clinical development is especially problematic for drugs directed at CNS-specific targets. For drugs with a novel mechanism of action, these problems are often greater. We describe Xanamem's clinical pharmacology, including the approach to dose selection and proof-of-concept studies.
View Article and Find Full Text PDFBackground: Alzheimer's disease (AD) is a neurodegenerative disorder without a cure. Targeting this multifactorial disease by repurposing FDA approved drugs serves as a faster mode of treatment due to its pre-established human safety. We tested terazosin (TZ), an a-1 adrenergic receptor (AR) antagonist and phosphoglycerate kinase-1 (PGK1) activator as having potential to treat AD.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Background: Acetylcholine, a neurotransmitter critical for cognitive functions, including attention, memory, and sociability, is essential for maintaining synaptic integrity. Deficits in acetylcholine levels are linked to cognitive impairments. Heterozygous VAChT KD (VAChT KDHET) mice, characterized by reduced vesicular acetylcholine transporter protein production, exhibit cognitive impairments due to diminished acetylcholine release.
View Article and Find Full Text PDFBackground: The increased incidence of Alzheimer's disease (AD) rate represent an unmet medical need and thus critical for the development of novel molecular therapeutics. Recent work focusing on patients with apoE4 alleles has highlighted the association of brain cholesterol dysregulation with elevated pathological burden and neurodegeneration. These studies have highlighted the importance of the nuclear receptor Liver X receptor (LXR) for developing AD therapies.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!